A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
← catalyst calendarNCT07102381 · readout in 500 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Jazz Pharmaceuticals Ireland Limited.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
125estimated
Sites
33
Countries
Italy, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-24 | actual | When the study began enrolling |
| Primary completion | 2028-01-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- HER2-positive Breast Cancer
- Breast Cancer
Interventions
- Drug: Zanidatamab — also filed as ZW25, JZP598, ZIIHERA®
- Drug: Paclitaxel
- Drug: Docetaxel
- Drug: Carboplatin
- Drug: Trastuzumab
- Drug: Pertuzumab
Primary outcome
what the primary-completion date above is the date OFNumber of participants with pCR
measured Up to 8 months
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed